Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.32 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17790435 | 0.85 | — | — | |
| SCHEMBL9360077 | 0.77 | CYP19A1 (0.34) | HSD11B1 | |
| SCHEMBL12727654 | 0.76 | MEN1 (0.34) | MEN1CYP2C9KMT2ATRIM24TRIM33 | |
| SCHEMBL3797017 | 0.73 | — | — | |
| SCHEMBL28982664 | 0.72 | MEN1 (0.32) | MEN1CYP2C9KMT2ATRIM24TRIM33 | |
| SCHEMBL22690012 | 0.72 | TRIM24 (0.36) | MEN1CYP2C9KMT2ATRIM24TRIM33 | |
| SCHEMBL9998382 | 0.72 | OPRM1 (0.36) | MEN1CYP2C9KMT2ATRIM24TRIM33 | |
| SCHEMBL9543026 | 0.72 | — | — | |
| SCHEMBL9500035 | 0.72 | TRIM24 (0.32) | TRIM24TRIM33ALDH1A1 | |
| SCHEMBL307642 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210128528-A1 | USE OF 5HT2A INVERSE AGONISTS FOR TREATING PSYCHOSIS | AXOVANT SCIENCES GMBH (CH) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210128528-A1 | USE OF 5HT2A INVERSE AGONISTS FOR TREATING PSYCHOSIS | HTR2A, HTR1A, HTR3B | MEN1 3031/4885CYP2C9 2479/4885KMT2A 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.